Xeljanz
E474935
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Xeljanz canonical | 1 |
| tofacitinib | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4850383 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Xeljanz Context triple: [Pfizer, developed, Xeljanz]
-
A.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
B.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
C.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
D.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
E.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Xeljanz Target entity description: Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
-
A.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
B.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
C.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
D.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
E.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
Janus kinase inhibitor
ⓘ
immunosuppressive agent ⓘ pharmaceutical drug ⓘ small molecule drug ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| approvedIn |
European Union
ⓘ
United States ⓘ
linked to:
United States of America
|
| belongsToTherapeuticClass |
disease-modifying antirheumatic drugs
ⓘ
targeted synthetic DMARDs ⓘ |
| contraindicatedIn |
hypersensitivity to tofacitinib
ⓘ
severe hepatic impairment ⓘ |
| developedBy | Pfizer ⓘ |
| hasActiveIngredient | tofacitinib ⓘ |
| hasATCCode | L04AA29 ⓘ |
| hasBlackBoxWarning |
increased risk of mortality
ⓘ
malignancy and thrombosis ⓘ risk of serious infections ⓘ |
| hasBrandOwner | Pfizer ⓘ |
| hasCommonAdverseEffect |
diarrhea
ⓘ
headache ⓘ nasopharyngitis ⓘ upper respiratory tract infection ⓘ |
| hasDosageForm |
extended-release tablet
ⓘ
oral tablet ⓘ |
| hasInternationalNonproprietaryName |
tofacitinib
ⓘ
linked to:
Xeljanz
|
| hasMechanismOfAction | Janus kinase (JAK) pathway inhibition ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
major adverse cardiovascular events
ⓘ
malignancy ⓘ serious infections ⓘ thrombosis ⓘ |
| indicatedFor |
active ankylosing spondylitis
ⓘ
active polyarticular course juvenile idiopathic arthritis ⓘ active psoriatic arthritis ⓘ moderate to severe rheumatoid arthritis ⓘ moderately to severely active ulcerative colitis ⓘ |
| isAdministeredWith | or without food ⓘ |
| regulates | cytokine signaling involved in immune response ⓘ |
| requiresMonitoringOf |
hemoglobin
ⓘ
lipid levels ⓘ liver enzymes ⓘ lymphocyte counts ⓘ neutrophil counts ⓘ |
| targets |
Janus kinase 1
ⓘ
Janus kinase 3 ⓘ |
| usedFor |
ankylosing spondylitis
ⓘ
polyarticular course juvenile idiopathic arthritis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Xeljanz Description of subject: Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.